(2) Swirl or roll gently until clear never shake
A 104-week carcinogenicity study was conducted in male and female Sprague Dawley rats at doses of 0.075, 0.25 and 0.75 mg/kg/day liraglutide administered by bolus subcutaneous injection with exposures 0.5-, 2- and 8-times the human exposure, respectively, resulting from the MRHD based on plasma AUC comparison
Safety and Tolerability: To address our secondary objectives of safety and tolerability, adverse events were monitored throughout the study based on prior studies (18,19) via medical history, vital signs, physical examination, and standard laboratory assessments (hematology, biochemistry, coagulation, urinalysis)
Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial